百利天恒双抗ADC达到Ⅲ期临床试验主要终点 为三阴性乳腺癌治疗提供新选项

每日经济新闻
Feb 24

2月23日,百利天恒(SH688506,股价289.59元,市值1195.6亿元)宣布其自主研发的全球首创EGFR×HER3双抗ADC药物(抗体偶联药物)iza-bren,在针对局部晚期或转移性三阴性乳腺癌(TNBC)的Ⅲ期临床试验中取得突破。  期中分析数据显示,该药物显著延长了患者的无进展生存期(PFS)和总生存期(OS),达到双主要终点。这不仅标志着iza-bren成为全球首个在TNBC治疗...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10